SOURCE-LINKED STUDY SUMMARY
Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.
Abstract summarizedQuality not appraised
- What was studied
- This 48-hour cell experiment compared untreated HepG2 liver cells, free-fatty-acid-treated cells, and fatty-acid-treated cells exposed to liraglutide. It measured cellular lipids, oxidative-stress markers, iron, and antioxidant activity.
- Who / model studied
- The model used HepG2 cells rather than animals or people; the abstract did not state the number of cell replicates.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Liraglutide partially reversed fatty-acid-induced changes, reducing malondialdehyde and iron while lowering TFR1 and increasing NRF2 and GPX4 expression.
- Limitations & context
- This was a cell-line mechanism study, so it does not establish clinical liver protection or safety in humans.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.